In a year’s time, officials with St. Luke’s said, they expect the FDA to greenlight the device.
“Basically, we put an electrode on the spine,” said Steven M. Falowski, MD, a neurosurgeon with St. Luke’s. “Normally, with this kind of surgery we stimulate nerves that are creating pain. So, patients would get a tingly sensation. With the new device, a patient gets the pain relief without the tingling or any other sensation.”
So far, Dr. Falowski said he’s implanted the device into five patients, who have all cut their pain medication in half or not longer take it at all. He added that he hopes to get 10 to 15 more patients to agree to enroll in the study over the next months.
Officials with St. Luke’s credited Dr. Falowski as being one of the biggest reasons the healthcare provider was able to proceed with the study — and, for his part, Dr. Falowski said he is happy with the study, and the results of the device, so far.
“This is not a last-resort therapy. It is an in-and-out surgery that gives comfort to people who are in extreme chronic pain for a long time,” he said. “We help people with a disability get back to work. We give them back their quality of life.”
For more spine and orthopedic news:
Dymicron’s cervical TDR device receives CE Mark approval
Medtronic-Covidien deal could be done today — 5 things to know
10 key updates on Titan Spine — 27k implantations and growing
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
